Cargando…
Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo
Overexpression of the multidrug resistance (MDR)-related protein P-glycoprotein (PGP1), which actively extrudes chemotherapeutic agents from cells and significantly decreases the efficacy of chemotherapy, is viewed as a major obstacle in osteosarcoma chemotherapy. Anlotinib, a novel tyrosine kinase...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801797/ https://www.ncbi.nlm.nih.gov/pubmed/35111065 http://dx.doi.org/10.3389/fphar.2021.798837 |
_version_ | 1784642542990524416 |
---|---|
author | Wang, Gangyang Cao, Lingling Jiang, Yafei Zhang, Tao Wang, Hongsheng Wang, Zhuoying Xu, Jing Mao, Min Hua, Yingqi Cai, Zhengdong Ma, Xiaojun Hu, Shuo Zhou, Chenghao |
author_facet | Wang, Gangyang Cao, Lingling Jiang, Yafei Zhang, Tao Wang, Hongsheng Wang, Zhuoying Xu, Jing Mao, Min Hua, Yingqi Cai, Zhengdong Ma, Xiaojun Hu, Shuo Zhou, Chenghao |
author_sort | Wang, Gangyang |
collection | PubMed |
description | Overexpression of the multidrug resistance (MDR)-related protein P-glycoprotein (PGP1), which actively extrudes chemotherapeutic agents from cells and significantly decreases the efficacy of chemotherapy, is viewed as a major obstacle in osteosarcoma chemotherapy. Anlotinib, a novel tyrosine kinase inhibitor (TKI), has good anti-tumor effects in a variety of solid tumors. However, there are few studies on the mechanism of anlotinib reversing chemotherapy resistance in osteosarcoma. In this study, cellular assays were performed in vitro and in vivo to evaluate the MDR reversal effects of anlotinib on multidrug-resistant osteosarcoma cell lines. Drug efflux and intracellular drug accumulation were measured by flow cytometry. The vanadate-sensitive ATPase activity of PGP1 was measured in the presence of a range of anlotinib concentrations. The protein expression level of ABCB1 was detected by Western blotting and immunofluorescence analysis. Our results showed that anlotinib significantly increased the sensitivity of KHOSR2 and U2OSR2 cells (which overexpress PGP1) to chemotherapeutic agents in vitro and in a KHOSR2 xenograft nude mouse model in vivo. Mechanistically, anlotinib increases the intracellular accumulation of PGP1 substrates by inhibiting the efflux function of PGP1 in multidrug-resistant cell lines. Furthermore, anlotinib stimulated the ATPase activity of PGP1 but affected neither the protein expression level nor the localization of PGP1. In animal studies, anlotinib in combination with doxorubicin (DOX) significantly decreased the tumor growth rate and the tumor size in the KHOSR2 xenograft nude mouse model. Overall, our findings suggest that anlotinib may be useful for circumventing MDR to other conventional antineoplastic drugs. |
format | Online Article Text |
id | pubmed-8801797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88017972022-02-01 Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo Wang, Gangyang Cao, Lingling Jiang, Yafei Zhang, Tao Wang, Hongsheng Wang, Zhuoying Xu, Jing Mao, Min Hua, Yingqi Cai, Zhengdong Ma, Xiaojun Hu, Shuo Zhou, Chenghao Front Pharmacol Pharmacology Overexpression of the multidrug resistance (MDR)-related protein P-glycoprotein (PGP1), which actively extrudes chemotherapeutic agents from cells and significantly decreases the efficacy of chemotherapy, is viewed as a major obstacle in osteosarcoma chemotherapy. Anlotinib, a novel tyrosine kinase inhibitor (TKI), has good anti-tumor effects in a variety of solid tumors. However, there are few studies on the mechanism of anlotinib reversing chemotherapy resistance in osteosarcoma. In this study, cellular assays were performed in vitro and in vivo to evaluate the MDR reversal effects of anlotinib on multidrug-resistant osteosarcoma cell lines. Drug efflux and intracellular drug accumulation were measured by flow cytometry. The vanadate-sensitive ATPase activity of PGP1 was measured in the presence of a range of anlotinib concentrations. The protein expression level of ABCB1 was detected by Western blotting and immunofluorescence analysis. Our results showed that anlotinib significantly increased the sensitivity of KHOSR2 and U2OSR2 cells (which overexpress PGP1) to chemotherapeutic agents in vitro and in a KHOSR2 xenograft nude mouse model in vivo. Mechanistically, anlotinib increases the intracellular accumulation of PGP1 substrates by inhibiting the efflux function of PGP1 in multidrug-resistant cell lines. Furthermore, anlotinib stimulated the ATPase activity of PGP1 but affected neither the protein expression level nor the localization of PGP1. In animal studies, anlotinib in combination with doxorubicin (DOX) significantly decreased the tumor growth rate and the tumor size in the KHOSR2 xenograft nude mouse model. Overall, our findings suggest that anlotinib may be useful for circumventing MDR to other conventional antineoplastic drugs. Frontiers Media S.A. 2022-01-17 /pmc/articles/PMC8801797/ /pubmed/35111065 http://dx.doi.org/10.3389/fphar.2021.798837 Text en Copyright © 2022 Wang, Cao, Jiang, Zhang, Wang, Wang, Xu, Mao, Hua, Cai, Ma, Hu and Zhou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wang, Gangyang Cao, Lingling Jiang, Yafei Zhang, Tao Wang, Hongsheng Wang, Zhuoying Xu, Jing Mao, Min Hua, Yingqi Cai, Zhengdong Ma, Xiaojun Hu, Shuo Zhou, Chenghao Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo |
title | Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo |
title_full | Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo |
title_fullStr | Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo |
title_full_unstemmed | Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo |
title_short | Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo |
title_sort | anlotinib reverses multidrug resistance (mdr) in osteosarcoma by inhibiting p-glycoprotein (pgp1) function in vitro and in vivo |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801797/ https://www.ncbi.nlm.nih.gov/pubmed/35111065 http://dx.doi.org/10.3389/fphar.2021.798837 |
work_keys_str_mv | AT wanggangyang anlotinibreversesmultidrugresistancemdrinosteosarcomabyinhibitingpglycoproteinpgp1functioninvitroandinvivo AT caolingling anlotinibreversesmultidrugresistancemdrinosteosarcomabyinhibitingpglycoproteinpgp1functioninvitroandinvivo AT jiangyafei anlotinibreversesmultidrugresistancemdrinosteosarcomabyinhibitingpglycoproteinpgp1functioninvitroandinvivo AT zhangtao anlotinibreversesmultidrugresistancemdrinosteosarcomabyinhibitingpglycoproteinpgp1functioninvitroandinvivo AT wanghongsheng anlotinibreversesmultidrugresistancemdrinosteosarcomabyinhibitingpglycoproteinpgp1functioninvitroandinvivo AT wangzhuoying anlotinibreversesmultidrugresistancemdrinosteosarcomabyinhibitingpglycoproteinpgp1functioninvitroandinvivo AT xujing anlotinibreversesmultidrugresistancemdrinosteosarcomabyinhibitingpglycoproteinpgp1functioninvitroandinvivo AT maomin anlotinibreversesmultidrugresistancemdrinosteosarcomabyinhibitingpglycoproteinpgp1functioninvitroandinvivo AT huayingqi anlotinibreversesmultidrugresistancemdrinosteosarcomabyinhibitingpglycoproteinpgp1functioninvitroandinvivo AT caizhengdong anlotinibreversesmultidrugresistancemdrinosteosarcomabyinhibitingpglycoproteinpgp1functioninvitroandinvivo AT maxiaojun anlotinibreversesmultidrugresistancemdrinosteosarcomabyinhibitingpglycoproteinpgp1functioninvitroandinvivo AT hushuo anlotinibreversesmultidrugresistancemdrinosteosarcomabyinhibitingpglycoproteinpgp1functioninvitroandinvivo AT zhouchenghao anlotinibreversesmultidrugresistancemdrinosteosarcomabyinhibitingpglycoproteinpgp1functioninvitroandinvivo |